Abstract
A structurally novel pyrazolo[1,5-c]quinazoline, SQ 13,847, was demonstrated to be an orally active antiallergic agent. The compound inhibited immunoglobulin (Ig)E-mediated passive cutaneous anaphylaxis (PCA) and passive pulmonary anaphylaxis in the rat (ID50 = 2 to 4 mg/kg p.o.), but failed to affect IgG-mediated PCA in the rat, IgE-mediated PCA in the mouse or IgG1-mediated PCA in the guinea pig. The relative potencies of SQ 13,847 and its 2-carboxylic acid metabolite, SQ 12,903, upon oral vs. intravenous administration were consistent with a role of SQ 13,847 as an orally absorbed prodrug of SQ 12,903. In the rat, SQ 13,847 is not an antagonist of histamine in serotonin, in beta adrenergic agonist or a bronchodilator.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.